Effect of Febuxostat on Flow Mediated Diameter in hyperuricemia patients with chronic kidney disease 5D.

Trial Profile

Effect of Febuxostat on Flow Mediated Diameter in hyperuricemia patients with chronic kidney disease 5D.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2015

At a glance

  • Drugs Febuxostat (Primary)
  • Indications Hyperuricaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2015 Status changed from not yet recruiting to completed as per University Hospital Medical Information Network - Japan.
    • 13 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top